SUZANO/WOODSPIN
Woodspin, the exclusive producer and distributor of wood-based SPINNOVA® fibre, has obtained Forest Stewardship Council® (FSC) Chain of Custody certification. This recognizes that wood used by Woodspin for its manufacturing can be fully traced from its origin to the final fibre product, providing its customers with the assurance of sustainable sourcing.
Woodspin is a 50/50 joint venture between Suzano, the world’s largest hardwood pulp producer, and Spinnova, an innovative Finnish materials technology company. Woodspin uses responsibly grown eucalyptus hardwood planted, harvested, and sourced by Suzano on farms in Brazil. Suzano is the world’s largest eucalyptus grower and manages 26,000 km2 of land, of which 40 percent is set aside for permanent conservation.
FSC® is renowned as the most rigorous international standard for responsible forestry. FSC® certification ensures that a forest is being managed in a way that preserves biological diversity and benefits the lives of local people and workers while ensuring it sustains economic viability.
Woodspin produces the unique, wood-based SPINNOVA® fibre without harmful chemicals or pollution. SPINNOVA® fibre has a 74 percent smaller life cycle carbon footprint and 98 percent less water consumption than conventional cotton.* The exclusive use of Suzano’s eucalyptus-based raw materials enables Woodspin to guarantee end-to-end traceability while remaining committed to zero deforestation and upholding comprehensive ethical and sustainable practices.
Jari Aittakari, Sales Director at Woodspin, said:
“Consumers and stakeholders at every stage of the textiles value chain deserve to know the origin of the products they buy, that these have been ethically produced, and that the materials used to make them have been sustainably sourced.
We recognize that the demand for supply chain transparency is increasing. This FSC® certification demonstrates to our partners – be that brands or producers – that Woodspin’s SPINNOVA® fibre is produced to the highest standard, from farm to fibre, without compromise.”
Fabian Farkas, Chief Markets Officer at FSC® International, said:
“As the forestry sector continues to push boundaries through innovation, key players are increasingly recognizing FSC® as the solution provider for responsible sourcing. Woodspin's FSC® Chain of Custody certification is such a significant milestone, paving the way for a more sustainable and scalable textile fibre production and ultimately a fossil fuel-free world.”
This certification follows the 2023 opening of Woodspin’s first facility producing wood-based SPINNOVA® fibre in Jyväskylä, Finland. This plant produces biodegradable textile fibres, enabling garments with hand feel close to the natural fibres made responsively from trees. Woodspin’s modern facility uses Spinnova’s fibre technology, which is designed to produce zero waste. It uses an advanced energy recovery system to recycle its only by-product – surplus heat – which can be reused in a local heating network.
The wood-based SPINNOVA® fibre is already being used by global fashion brands such as adidas and Bestseller.
About Woodspin
Woodspin is the exclusive producer and seller of wood-based SPINNOVA® fibre, a sustainable, recyclable, material made from trees. Woodspin is a 50/50 joint venture between the world’s largest hardwood pulp producer, Suzano, and Spinnova, an innovative Finnish materials technology company. Woodspin’s unique product fuses the responsibly-grown eucalyptus hardwood of Suzano with the pioneering technology of Spinnova. In our process we use radically less water and fewer CO2 emissions than alternative fibres, requiring no harmful chemicals, and leaving no waste by-products. http://woodspin.com/
About FSC ®
FSC® is a non-profit organization that provides a proven sustainable forest management solution. Currently, over 150 million hectares of forest worldwide is certified according to FSC® standards. It is widely regarded as the most rigorous forest certification system among NGOs, consumers, and businesses alike to tackle today’s deforestation, climate, and biodiversity challenges. The FSC® forest management standard is based on ten core principles designed to address a broad range of environmental, social and economic factors. FSC’s “check tree” label is found on millions of forest-based products and verifies that they are sustainably sourced, from forest to consumer. www.fsc.org.
About SPINNOVA – Sustainable textile materials, naturally
Spinnova transforms the way textiles are manufactured globally. Based in Finland, Spinnova has developed breakthrough patented technology for making textile fibre out of wood or waste, such as leather, textile or agricultural waste, without harmful chemicals. The SPINNOVA® fibre creates zero waste, and its CO2 emissions and water consumption are minimal. SPINNOVA® fibre is biodegradable and recyclable.
Spinnova is committed to using only sustainable raw materials such as FSC certified wood and waste. SPINNOVA® fibre is produced without harmful or complex chemical processes, and has the touch and feel of natural fibres such as cotton and linen. Spinnova has received awards from Fast Company, ISPO, Scandinavian Outdoor, ANDAM, Monocle and Marie Claire UK.
Spinnova’s shares (SPINN) are listed on the Nasdaq First North Growth Market Finland.
SPINNOVA® home: www.spinnova.com
Corporate & IR site: www.spinnovagroup.com
About Suzano
Suzano is the world’s largest producer of market pulp. Our responsibly grown raw materials are used in products reaching over two billion people in more than 100 countries, including tissue and toilet paper, books, printing and writing paper, diapers and period products, packaging, textiles, and a range of innovative applications that can replace products made from fossil fuels.
Our pulp is made using biomass produced from farmed eucalyptus trees, offering a biodegradable, renewable and recyclable raw material for consumer and industrial use. We plant 1.2 million trees a day and only harvest what we plant. We manage around 26,000 km2 of land and around 40% of this is protected for permanent conservation, with a zero deforestation policy across all of our operations.
Suzano’s history goes back over 100 years. We are listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States. Learn more at: www.suzano.com.br/en.
Disclaimer
*CO2e emission comparison is based on a projected product carbon footprint conducted by a third-party expert following the ISO 14067:2018 standard. Ecoinvent database has been used as the source for global average CO2e emissions of conventional cotton. Water consumption comparison is based on a projected, screening Life Cycle Assessment (LCA) conducted by a third-party expert. Both comparisons include raw material supply, transportation of raw materials, and manufacturing of the product (cradle-to-gate).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510834910/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom